Restaurant Brands International Currently Down Eight Consecutive Days, On Track for Longest Losing Streak Since June 2017 — Data Talk
Restaurant Brands International, Inc. (QSR) is currently at $72.44, down $1.80 or 2.42%
--Would be lowest close since Dec. 11, 2023, when it closed at $72.30
--Currently down eight consecutive days; down 8.82% over this period
--Longest losing streak since June 12, 2017, when it fell for nine straight trading days
--Worst eight day stretch since the eight days ending Sept. 30, 2022, when it fell 9%
--Down 8.82% month-to-date
--Down 7.28% year-to-date
--Down 12.45% from its all-time closing high of $82.75 on March 13, 2024
--Up 8.84% from 52 weeks ago (April 12, 2023), when it closed at $66.56
--Down 12.45% from its 52-week closing high of $82.75 on March 13, 2024
--Up 15.6% from its 52-week closing low of $62.67 on Oct. 13, 2023
--Traded as low as $72.36; lowest intraday level since Dec. 12, 2023, when it hit $72.00
--Down 2.53% at today's intraday low
All data as of 11:20:15 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 10, 2024 11:38 ET (15:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?